| Target Price | $66.30 |
| Price | $69.85 |
| Deviation |
5.08%
register free of charge
|
| Number of Estimates | 19 |
|
19 Analysts have issued a price target Avidity Biosciences Inc 2026 .
The average Avidity Biosciences Inc target price is $66.30.
This is
5.08%
register free of charge
$100.80
44.31%
register free of charge
$52.52
24.81%
register free of charge
|
|
| A rating was issued by 22 analysts: 21 Analysts recommend Avidity Biosciences Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Avidity Biosciences Inc stock has an average upside potential 2026 of
5.08%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 10.90 | 9.72 |
| 14.02% | 10.85% | |
| EBITDA Margin | -3,451.01% | -7,025.62% |
| 41.29% | 103.58% | |
| Net Margin | -2,956.88% | -5,579.87% |
| 33.20% | 88.71% |
16 Analysts have issued a sales forecast Avidity Biosciences Inc 2025 . The average Avidity Biosciences Inc sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Avidity Biosciences Inc EBITDA forecast 2025. The average Avidity Biosciences Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
18 Avidity Biosciences Inc Analysts have issued a net profit forecast 2025. The average Avidity Biosciences Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.89 | -4.49 |
| 0.69% | 55.36% | |
| P/E | negative | |
| EV/Sales | 927.06 |
18 Analysts have issued a Avidity Biosciences Inc forecast for earnings per share. The average Avidity Biosciences Inc EPS is
This results in the following potential growth metrics and future valuations:
Avidity Biosciences Inc...
| Analyst | Rating | Action | Date |
|---|---|---|---|
| TD Cowen |
Locked
➜
Locked
|
Locked | Oct 29 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Oct 28 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Oct 28 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Oct 27 2025 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | Oct 27 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 27 2025 |
| Bernstein |
Locked
➜
Locked
|
Locked | Oct 27 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
TD Cowen:
Locked
➜
Locked
|
Oct 29 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Oct 28 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Oct 28 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Oct 27 2025 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Oct 27 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 27 2025 |
|
Locked
Bernstein:
Locked
➜
Locked
|
Oct 27 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


